Drugs / FOV2302
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00969293 | Sep 2009 → Jul 2011 | central retinal vein occlusion, macular retinal edema | Fovea Pharmaceuticals SA | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FOV2302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00969293 ↗ |
| Known as | Ecallantide | “FOV2302 (Ecallantide)” NCT00969293 ↗ |
| Route | Intravitreal | “Single intravitreal injection into the relevant eye.” NCT00969293 ↗ |